The Intellectual Property & Science business of Thomson Reuters has announced the launch of Precision Medicine Intelligence, a new evidence-based solution dedicated to helping scientists and physicians understand and keep pace with the rapid growth of scientific and medical literature.
The announcement was made at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, an annual gathering of over 30,000 oncology professionals from around the world, held at McCormick Place in Chicago, Illinois.
The Thomson Reuters Precision Medicine Intelligence provides a structured database of evidence-based clinical outcomes designed to empower concise, accurate and clinically meaningful interpretation of molecular test results. This helps users to keep up to date with genomics knowledge to validate and interpret relevant variant associations, translating the complexity of gene data into clinically actionable insights. Precision Medicine Intelligence also supports patient segment definition and stratification for clinical research, accelerating drug development to ultimately drive new research and clinical development strategies.
The solution, which is delivered via an API and through partner platforms, integrates intelligence from a wide variety of global sources, including full text peer-reviewed journals, clinical guidelines, clinical trials and regulatory drug approvals. Drawing on Thomson Reuters' decades of expertise in curating trusted scientific content for professionals, Precision Medicine Intelligence provides manually selected content in the following areas: Variants; Clinical Trials; Drugs; and Gene Biomarkers.
Brought to you by Scope e-Knowledge Center, a world-leading provider of metadata services, abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
